– USA, TX – CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer cell therapy, today announced the appointment of Jason Wilson to the company’s board of directors. Mr. Wilson, who currently serves as the Chief Financial Officer of Reata Pharmaceuticals, Inc., brings more than 20 years of experience in corporate finance and life science operations to CytoSen’s Board.
Co-Founder Dr. Dean Lee has stepped off the CytoSen Corporate Board to make room for Mr. Wilson, and will continue to serve as Chairman of CytoSen’s Science Advisory Board as he also continues to concentrate on his NK cell research at Nationwide Children’s Hospital, where CytoSen maintains a Sponsored Research relationship.
CytoSen chairman McKee said “I believe Dr. Lee’s ongoing research at NCH will be a big part of our future success.”
“We are very fortunate to have someone of Jason Wilson’s caliber and experience join the CytoSen Board of Directors,” said Chairman Philip R. McKee. “Our company and technology development are at critical stages, and we need experienced leadership at the board level to successfully implement our strategy and take advantage of the market opportunities ahead. Jason is a biotech veteran with a proven track record of execution who brings talent and energy to CytoSen, and has already developed a solid understanding of our science and opportunities.”
About Jason Wilson
Mr. Wilson joined Reata in 2006, and has played a key role in helping to grow the company from a startup through its 2016 initial public offering. He currently leads corporate strategy, finance, accounting, treasury, human resources, business development, investor relations and information technology at Reata. Prior to joining Reata, he held positions as Vice President, Finance & Corporate Controller at Caris Diagnostics and Senior Manager in the health-sciences group at Ernst & Young LLP. Mr. Wilson holds a B.B.A. in Accounting from Henderson University, an M.B.A. from the University of Central Arkansas and is a CPA.
About CytoSen’s NK Cell Platform
NK cells play a significant role in the body’s innate immune response, circulating through the body to rapidly recognize and kill cancerous cells. CytoSen’s nanoparticle processing technology enables improved and sustained growth of high-dose NK cells that have high anti-cancer cytotoxicity as well as increased expansion and activation capabilities. CytoSen’s lead product, CSTD002-NK, is poised to enter Phase 2 clinical studies in the U.S. in the first half of 2019 as a best-in-class NK cell therapy for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in HSCT patients.
CytoSen’s technology platform is based on the work of Dean Lee, M.D., Ph.D., Director of the Cellular Therapy and Cancer Immunotherapy Program for Nationwide Children’s Hospital’s Division of Hematology/Oncology/BMT and Center for Childhood Cancer and Blood Diseases, and Stefan Ciurea, M.D., Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. Data from Phase I/II clinical trials at MDACC demonstrated compelling results in treating AML.
About CytoSen Therapeutics, Inc.
CytoSen is a private biopharmaceutical company on the front line of advancing clinical development of next generation NK cells with the first scalable, therapeutic platform for high dose, cancer-killing NK cells calibrated to each cancer target while reinforcing immune defenses.
Born from the intersection of cellular immunotherapy and nanotechnology, CytoSen’s NK cell therapy harnesses the power of the immune system to treat cancer.
For more information : http://www.cytosen.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.